The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy

Author(s): Carlos G. Ferreira, Andrea Nicolini*, Liliana Dalurzo, Stephen Stefani, Vanessa Teich, Natasha Leighl.

Journal Name: Current Drug Targets

Volume 20 , Issue 1 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The development of therapies that restore or activate the host immune response – the socalled “immuno-oncologic” therapy – has improved the survival of some cancer patients harboring specific tumor types. These drugs, however, are very expensive which has greatly limited their use and consequently reduced the number of patients who could likely benefit. Not to mention, the proportion of patients who display a clinical benefit from therapy is limited. Thus, from a clinical and health economics perspective, there is a pressing need to identify and treat those patients for whom a given immuno- oncologic therapy is most likely to be beneficial. At this end, the identification, validation and use of biomarkers emerge as an important therapeutic tool. Here, we briefly review the state of immunologic biomarker development and utilization and make suggestions for interested clinicians, health policy makers and other stakeholders to prepare for the broader use of biomarkers associated with immuno-oncologic therapy in routine practice. The biomarker field is clearly in its earliest stages and there is no doubt that continued research will identify new biomarkers with valuable clinical indications. Of course, the clinical utility of a biomarker must consider patient preferences and perspectives. In addition, health economic analyses are crucial to better define the value of immunotherapy based on precision medicine strategies and promote value-based pricing.

Keywords: Biomarkers, immuno-oncology, immuno-oncologic therapy, cancer, biological molecule, clinical oncology.

[1]
National Cancer Institute. (2017). NCI Dictionary of Cancer Terms. [online] Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618 [Accessed 8 Nov. 2017].
[2]
Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer biomarkers discovery and validation: State of the art, problems and future perspectives. Adv Exp Med Biol 2015; 867: 9-26.
[3]
Gnjatic S, Bronte V, Brunet L, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J ImmunoTherapy Cancer 2017; 5(1)
[4]
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 2017; 24: 26.
[5]
Herbst R, Baas P, Kim D, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 2016; 387(10027): 1540-50.
[6]
Sholl LM, Aisner DL, Allen TC, et al. Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists: A perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 2016; 140(4): 341-4.
[7]
Le D, Uram J, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med 2015; 372(26): 2509-20.
[8]
Le D, Durham J, Smith K, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357(6349): 409-13.
[9]
Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25(3): 611-8.
[10]
Cesano A, Warren S. Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines 2018; 6(1): 14.
[11]
Sheerens H, Malong A, Bassett K, et al. Current status of companion and complementary diagnostics: Strategic considerations for development and launch. Trends Pharmacol Sci 2017; 10(2): 84-92.
[12]
Beaver J, Tzou A, Blumenthal G, et al. An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies. Clin Cancer Res 2016; 23(6): 1368-72.
[13]
Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The challenge for development of valuable immune-oncology biomarkers. Clin Cancer Res 2017; 23(17): 4970-9.
[14]
Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. ; N Engl J Med 2016. 1;375(9): 819-29.
[15]
Hirsch F, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017; 12(2): 208-22.
[16]
Rimm DL. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncology 2017; 1; 3(8): 1051-58.
[17]
Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol 2016; 11(11): 1846-55.
[18]
Ferreira CG, Melo AC, Stefani S, et al. Increasing access to immuno-oncology therapies in brazil. J Cancer Policy 2018; 16: 1-5.
[19]
Baik C, Rubin E, Forde P, et al. Immuno-oncology clinical trial design: limitations, challenges and opportunities. Clin Cancer Res 2017; 23: 4992-5002.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 1
Year: 2019
Page: [81 - 86]
Pages: 6
DOI: 10.2174/1389450119666180911093143
Price: $58

Article Metrics

PDF: 27
HTML: 5